CIRCULATING FIBROCYTES IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS: CORRELATION WITH DERMAL THICKNESS

Barbara Ruaro1, Stefano Soldano1, Vanessa Smith2,3, Sabrina Paolino1, Carmen Pizzorni1, Paola Contila1, Paola Montagna1, Samuele Tarullo1, Maurizio Cutolo1. 1Research Laboratory and Academic Division of Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy; 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; 3Department of Internal Medicine, Ghent University, Ghent, Belgium; 4Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Italy. 5Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.

Background: Systemic sclerosis (SSc) is characterized by early skin impairment (1,2) and the modified Rodnan skin score (mRSS) is the validated method to assess the severity of this impairment. Whilst skin high frequency ultrasound (US) is a relatively new technique to measure dermal thickness (DT) (2-4).

Recent findings have reported the important contribution circulating fibrocytes make in the early stage of dermal repair and fibrosis. Indeed, as fibrocytes may be an important source of activated fibroblasts/myofibroblasts, it is reasonable to presume that they could be responsible for the increase in these cells observed in the tissue of SSc patients (5-7).

Objectives: The aim of this study was to identify any correlation between the modified Rodnan skin score (mRSS), dermal thickness (DT), measured by skin high frequency ultrasound (US) and the percentage of circulating fibrocytes in patients with limited cutaneous systemic sclerosis (lcSSc).

Methods: After obtaining approval and written informed consent and the Ethics Committee approval 8 lcSSc patients (7 females, 1 male) and 5 (4 females, 1 male) age-matched healthy volunteers (CNT) were enrolled. The lcSSc patients fulfilled the 2013 ACR/EULAR criteria for SSC (8). DT was evaluated by both mRSS and US (18 and 22 MHz probes), in all SSC patients and CNT, in the standard 17 skin areas evaluated by US and the percentage of circulating fibrocytes in patients with limited cutaneous systemic sclerosis (lcSSc).

Results: The percentage of circulating fibrocytes was positively correlated with DT-US, evaluated by the 22 MHz and the 18 MHz probes (p=0.04 and p=0.03, respectively) and mRSS (p=0.04) in lcSSc patients. Conversely, there was no correlation between these parameters in the CNT group (p=0.50).

Conclusion: The study demonstrates a significant relationship between DT, evaluated by both mRSS and US and the percentage of circulating fibrocytes in lcSSc patients. This observation may well support the hypothesis that circulating fibrocytes make a crucial contribution to skin fibrosis progression.

REFERENCE

Disclosure of Interests: None declared


AB0684 DO WE DIAGNOSE ALL THE ANTSYNTHESE SYNDROME?

Mertxell Salés Lizarazabu1, Sonia Minguéz1, Saul Mario Gelman1, Roser Tuneu1, Mercè López de Recalde1, Basilio Trápé1, Jaume Trapé2, Damià Perich3, 1Althaia Xarxa Asistencial Universitària de Manresa, Clinical Laboratory, Manresa, Spain; 2Althaia Xarxa Asistencial Universitària de Manresa, Rheumatology, Manresa, Spain; 3Althaia Xarxa Asistencial Universitària de Manresa, Internal Medicine, Manresa, Spain.

Background: Antisyntese syndrome (AS) is an autoimmune disease characterized by the presence of antianinoycic tRNA-synthetase antibodies (anti-ARS) and clinical manifestations that may include interstitial lung disease (ILD), myositis, non erosive arthritis, Raynaud’s phenomenon (RP), fever and mechanic’s hands. Until the Corrons diagnostic criteria appeared in 2010, these patients with anti-ARS antibody were classified as an idiopathic inflammatory myopathy, or if they did not present myositis, they remained undiagnosed.

Objectives: To identify patients with anti-ARS antibodies from our hospital since June 2015, when the immunology laboratory was inaugurated, and to verify if they fulfilled the AS criteria.

Methods: Retrospective observational study carried out in a regional hospital in Barcelona with a reference population of 260,000 inhabitants. All patients with any anti-ARS antibody (Jo1, PL7, PL12, EJ) positive were selected, determined by the Dot Blot Polymyositis/Scleroderma IgD T- and R-proteins, and then, they remained undiagnosed.

Results: We identified 18 patients with anti-ARS antibody, 9 anti-Jo1 (53%), 4 anti-PL7, 3 anti PL12 and 1 anti-EJ. Of these, 13 had values of ANA > 1/80, 3 values of 1/80 and 1 negative. Other antibodies identified were anti-Ro52 in 4, anti-DNA in 4 and anti-Scft1 in 1. All patients except one met AS criteria. None of anti-DNA positive subjects met criteria for rheumatoid systemic lupus or systemic sclerosis. The majority

Disclosure of Interests: None declared


AB0683 ROLE OF ELASTIN AND ELASTASE ANTIBODIES IN DEVELOPMENT OF PNEUMOCLEROSIS IN PATIENTS WITH SYSTEMIC SCLERODERMA


Background: Disturbed elastin metabolism, emerging pathological soluble isoforms followed by triggering of autoimmune reaction by the biopolymer under study is associated with the pathogenesis of polyorganic lesions in systemic sclerosis. Elastin catabolism is promoted by elastase, an enzyme with a broad–range substrate specificity. It is the balance of a dynamic elastin–elastase system that determines physiological functioning of organs and tissues containing elastic fibres: the skin, ligaments, lungs, and vascular walls. Antibodies to elastin and elastase are unique predictors of development of pulmonary conditions in systemic scleroderma, which are now considered one of risk factors for pulmonary lesion.

Objectives: Developing highly sensitive markers of pulmonary remodeling at early stages of systemic scleroderma with participation of humoral immunity to the elastin–elastase system in the development of pulmonary lesion in systemic scleroderma requires further detailed study.

Methods: Patients for the study were selected from the department of rheumatology at the Emergency Care Municipal Hospital 25 in the city of Volgograd. The main group incorporated 42 persons with the diagnosis of systemic scleroderma verified by ACR/EULAR diagnostic criteria of 2013, without any exclusion criteria. There were 11 men and 31 women aged 22–72 among the systemic scleroderma patients. The mean age of patients was 44.1±15.4. The control group incorporated 30 healthy donors at the Transfusion Regional Blood Transfusion Station. SSc patients and elastase were determined in the blood serum by indirect enzyme immunoassay utilizing insoluble forms with enhanced antigen content according to the original technique by Gontar et al (1990).

Results: Compared with the control group, patients with systemic scleroderma showed a considerably higher rate of antibodies to elastase (52%) and elastin (38%). The upper normal level of antibodies to elastin was in the range of 0.131 absorbance units, of antibodies to elastase – 0.131 absorbance units. The mean value of elastin antibodies in the blood of systemic scleroderma patients was 0.125 ± 0.068 absorbance units. The value of elastase antibodies was 0.143 ± 0.071 absorbance units. The elevated level of elastin and elastase antibodies in the patients was associated with pulmonary lesion (basal pulmonary fibrosis – 20 (47.6%); pulmonary hypertension – 11 (26.2%), and adhesive pleurisy – 7 (16.7%).) In one half of cases the pulmonary lesion was asymptomatic, detected by accessory investigations like X-ray of chest organs, respiratory function study, EchoCG which were administered to assess the extent of abdominal organ inflammation and in differential diagnosis with cardiac insufficiency. The level of elastin antibodies in systemic scleroderma patients with pulmonary lesion was 0.149 ± 0.074 absorbance units, and of elastase antibodies – 0.146 ± 0.043 absorbance units, which was considerably higher than mean values in the control group.

Conclusion: By determining antibodies to elastin and elastase by the proposed technique of enzyme immunoassay at early stages of systemic scleroderma one can predict lesions of pulmonary parenchyma presenting with various clinical signs, and exacerbation of fibrosis processes.

Disclosure of Interests: None declared